Adicet Bio 10-Q 8 May 15 2015 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2015	4-May-15
Document And Entity Information [Abstract]
Entity Registrant Name	ACETO CORP
Entity Central Index Key	2034
Trading Symbol	acet
Current Fiscal Year End Date	-24
Entity Filer Category	Accelerated Filer
Entity Common Stock Shares Outstanding		29,115,881
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$33,709	$42,897
Investments	1,834	746
Trade receivables, less allowance for doubtful accounts (March 31, 2015, $764; June 30, 2014, $517)	149,766	122,694
Other receivables	8,904	5,288
Inventory	97,216	100,683
Prepaid expenses and other current assets	2,757	3,556
Deferred income tax asset, net	1,361	490
Total current assets	295,547	276,354
Property and equipment, net	10,775	11,573
Property held for sale	5,848	5,848
Goodwill	67,848	66,516
Intangible assets, net	81,463	87,955
Deferred income tax asset, net	11,518	11,605
Other assets	8,622	8,133
TOTAL ASSETS	481,621	467,984
Current liabilities:
Current portion of long-term debt	9,697	8,343
Accounts payable	55,836	48,716
Accrued expenses	62,610	61,464
Total current liabilities	128,143	118,523
Long-term debt	97,510	97,158
Long-term liabilities	10,405	11,634
Environmental remediation liability	5,210	7,079
Deferred income tax liability	6	6
Total liabilities	241,274	234,400
Commitments and contingencies (Note 6)
Shareholders' equity:
Preferred stock, 2,000 shares authorized; no shares issued and outstanding
Common stock, $.01 par value, 40,000 shares authorized; 29,117 and 28,772 shares issued and outstanding at March 31, 2015 and June 30, 2014, respectively	291	288
Capital in excess of par value	92,329	87,156
Retained earnings	155,325	140,768
Accumulated other comprehensive (loss) income	-7,598	5,372
Total shareholders' equity	240,347	233,584
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$481,621	$467,984

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, except Per Share data, unless otherwise specified
Statement Of Financial Position [Abstract]
Trade receivables, allowance for doubtful accounts (in dollars)	$764	$517
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	40,000	40,000
Common stock, shares issued	29,117	28,772
Common stock, shares outstanding	29,117	28,772

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Net sales	$145,796	$124,830	$400,364	$370,599
Cost of sales	109,198	99,867	306,096	284,918
Gross profit	36,598	24,963	94,268	85,681
Selling, general and administrative expenses	19,067	16,381	56,320	47,212
Research and development expenses	2,101	1,504	3,223	3,232
Operating income	15,430	7,078	34,725	35,237
Other (expense) income:
Interest expense	-952	-310	-2,993	-1,200
Interest and other income, net	-852	1,136	24	2,171
Other (expense) income, Total	-1,804	826	-2,969	971
Income before income taxes	13,626	7,904	31,756	36,208
Income tax provision	5,215	2,548	11,909	12,762
Net income	$8,411	$5,356	$19,847	$23,446
Net income per common share (in dollars per share)	$0.29	$0.19	$0.69	$0.84
Diluted net income per common share (in dollars per share)	$0.29	$0.19	$0.68	$0.82
Weighted average shares outstanding:
Basic (in shares)	28,773	28,087	28,710	27,888
Diluted (in shares)	29,267	28,606	29,216	28,470

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income	$8,411	$5,356	$19,847	$23,446
Other comprehensive income:
Foreign currency translation adjustments	-6,011	-74	-12,968	3,082
Change in fair value of interest rate swaps	-155	36	-2	108
Comprehensive income	$2,245	$5,318	$6,877	$26,636

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating activities:
Net income	$19,847	$23,446
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	8,940	5,494
Provision for doubtful accounts	316	185
Non-cash stock compensation	3,407	2,416
Deferred income taxes	-1,000	-224
Earnings on equity investment in joint venture	-1,767	-1,769
Changes in assets and liabilities:
Trade accounts receivable	-33,084	-8,861
Other receivables	-3,616	-516
Inventory	-2,695	-14,068
Prepaid expenses and other current assets	649	-596
Other assets	1,261	1,332
Accounts payable	9,467	8,110
Accrued expenses and other liabilities	4,831	-1,863
Net cash provided by operating activities	6,556	13,086
Investing activities:
Payment for net assets of business acquired, net of cash acquired		-228
Purchases of investments	-1,120	-101
Sales of investments		501
Payments for intangible assets	-1,510	-662
Purchases of property and equipment, net	-581	-709
Net cash used in investing activities	-3,211	-1,199
Financing activities:
Payment of cash dividends	-5,232	-5,115
Proceeds from exercise of stock options	1,039	3,162
Excess tax benefit on stock option exercises and restricted stock	670	1,586
Payment of contingent consideration	-3,000
Payment of deferred consideration	-3,500	-1,500
Borrowings of bank loans	14,000	8,000
Repayment of bank loans	-12,294	-17,665
Net cash used in financing activities	-8,317	-11,532
Effect of exchange rate changes on cash	-4,216	797
Net (decrease) increase in cash	-9,188	1,152
Cash at beginning of period	42,897	33,231
Cash at end of period	$33,709	$34,383

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Mar. 31, 2015
Basis Of Presentation [Abstract]
Basis of Presentation	(1)  Basis of Presentation
	The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented.  Interim results are not necessarily indicative of results which may be achieved for the full year.
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements.  These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions.  The Company’s most critical accounting policies relate to revenue recognition; royalty income; partnered products; allowance for doubtful accounts; inventories; goodwill and other indefinite-lived intangible assets; long-lived assets; environmental and other contingencies; income taxes; and stock-based compensation.
	These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP.  Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the year ended June 30, 2014.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	(2)  Stock-Based Compensation
	At the annual meeting of shareholders of the Company, held on December 6, 2012, the Company’s shareholders approved the amended and restated Aceto Corporation 2010 Equity Participation Plan (the “2010 Plan”).  Under the 2010 Plan, grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses (collectively, “Stock Awards”) may be made to employees, non-employee directors and consultants of the Company, including the chief executive officer, chief financial officer and other named executive officers.  The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant.  Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock.  The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years.  The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.
	During the nine months ended March 31, 2015, the Company granted 165 shares of restricted common stock to its employees that vest over three years, 12 shares of restricted common stock to its non-employee directors, which vest over approximately one year, as well as 67 restricted stock units that have varying vest dates through August 2016.  In addition, the Company also issued a target grant of 116 performance-vested restricted stock units, which grant could be as much as 203 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.
	During the year ended June 30, 2014, the Company granted 214 shares of restricted common stock to its employees that vest over three years and 11 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 32 restricted stock units that have varying vest dates from August 2014 through July 2015. In addition, the Company also issued a target grant of 131 performance-vested restricted stock units, which grant could be as much as 196 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.
	For the three and nine months ended March 31, 2015  the Company recorded stock-based compensation expense of approximately $1,123 and $3,368, respectively, related to restricted common stock and restricted stock units. For the three and nine months ended March 31, 2014, the Company recorded stock-based compensation expense of approximately $606 and $2,225, respectively, related to restricted common stock and restricted stock units.   As of March 31, 2015, the total unrecognized compensation cost related to restricted stock awards and units is approximately $6,779.  There were no stock options granted in the nine months ended March 31, 2015 and 2014.  Total compensation expense related to stock options for the three and nine months ended March 31, 2015 was $0 and $21, respectively. Total compensation expense related to stock options for the three and nine months ended March 31, 2014 was $30 and $175, respectively.

Common_Stock

Common Stock	9 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Common Stock	(3)  Common Stock
	On May 7, 2015, the Company’s board of directors declared a regular quarterly dividend of $0.06 per share to be distributed on June 25, 2015 to shareholders of record as of June 11, 2015.
	On February 5, 2015, the Company’s board of directors declared a regular quarterly dividend of $0.06 per share which was paid on March 26, 2015 to shareholders of record as of March 12, 2015.
	On December 4, 2014, the Company’s board of directors declared a regular quarterly dividend of $0.06 per share which was paid on December 29, 2014 to shareholders of record as of December 15, 2014.
	On September 4, 2014, the Company’s board of directors declared a regular quarterly dividend of $0.06 per share which was paid on September 29, 2014 to shareholders of record as of September 15, 2014.
	On May 8, 2014, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2017.  Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase.
	The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.

Net_Income_Per_Common_Share

Net Income Per Common Share	9 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Income Per Common Share	(4)  Net Income Per Common Share
	Basic income per common share is based on the weighted average number of common shares outstanding during the period.  Diluted income per common share includes the dilutive effect of potential common shares outstanding.  The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding:
		Nine months ended				Three months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Weighted average shares outstanding		28,710		27,888		28,773		28,087
	Dilutive effect of stock options and restricted stock awards and units		506		582		494		519
	Diluted weighted average shares outstanding		29,216		28,470		29,267		28,606

Debt

Debt	9 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	(5) Debt
	Long-term debt
		March 31,		June 30,
		2015		2014
	Revolving bank loans	$	40,000	$	32,000
	Term bank loans		64,000		70,000
	Mortgage		3,207		3,355
	Other		-		146
			107,207		105,501
	Less current portion		9,697		8,343
		$	97,510	$	97,158
	Credit Facilities
	On April 30, 2014, and in connection with the purchase of PACK Pharmaceuticals, LLC (“PACK”), Aceto entered into a new Credit Agreement (the “Credit Agreement”) with three domestic financial institutions. The Credit Agreement terminated the Credit Agreement, dated December 31, 2010.  Aceto may borrow, repay and reborrow during the period ending April 30, 2019, up to but not exceeding at any one time outstanding $60,000 (the  “Revolving  Commitment”).  The Revolving Commitment provides for (i) Adjusted LIBOR Loans (as defined in the Credit Agreement), (ii) Alternate Base Rate Loans (as defined in the Credit Agreement) or (iii) a combination thereof.   As of March 31, 2015, the Company borrowed Revolving Loans aggregating $40,000 which loans are Adjusted LIBOR Loans at interest rates ranging from 2.22% to 2.32% at March 31, 2015. The Credit Agreement also allows for the borrowing up to $70,000 (the “Term Commitment”).  The Term Commitment interest may be payable as an (i) Adjusted LIBOR Loan, (ii) Alternate Base Rate Loan, or (iii) a combination thereof.  The Company borrowed a Term Loan of $70,000 on April 30, 2014 to partially finance the acquisition of PACK.  As of March 31, 2015, the remaining amount outstanding under the amortizing Term Loan is $64,000 and is payable as an Adjusted LIBOR Loan at an interest rate of 2.28% at March 31, 2015. Proceeds of the Term Commitment and a portion of the proceeds of the Revolving Commitment were used to fund the initial cash consideration for PACK and to repay the outstanding balance of term loans from the Credit Agreement dated December 31, 2010.
	The Term Loan is payable as to principal in nineteen consecutive quarterly installments, which commenced on September 30, 2014 and will continue on each December 31, March 31, and June 30 thereafter, each in the amount set forth below opposite the applicable installment, provided that the final payment on the Term Loan Maturity Date (as defined in the Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Term Loan:
	Installment	Amount
	1 through 4	$	2,000
	5 through 8	$	2,500
	9 through 12	$	3,000
	13 through 16	$	4,000
	17 through 19	$	6,000
	As such, the Company has classified $9,500 of the Term Loan as short-term in the consolidated balance sheet at March 31, 2015.  The Credit Agreement also provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services by us in the ordinary course of business. The Company had open letters of credit of approximately $21 and $105 at March 31, 2015 and June 30, 2014 respectively.  The terms of these letters of credit are all less than one year.  No material loss is anticipated due to non-performance by the counterparties to these agreements.
	The Credit Agreement provides for a security interest in all of our personal property.  The Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service. We are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, sale of assets, sales of receivables, and loans and investments. We were in compliance with all covenants at March 31, 2015.
	Mortgage
	On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its corporate headquarters, in Port Washington, New York. This mortgage is secured by the land and building and is being amortized over a period of 20 years. The mortgage, which was modified in October 2013, bears interest at 4.92% as of March 31, 2015 and matures on June 30, 2021.

Commitments_Contingencies_and_

Commitments, Contingencies and Other Matters	9 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments, Contingencies and Other Matters	(6)  Commitments, Contingencies and Other Matters
	The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable.  In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments.  If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss.  While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.
	On October 29, 2012, a lawsuit was filed in the United Kingdom (in the High Court of Justice, Queens Bench Division, Commercial Court) by United Phosphorous Limited (“UPL”) against Aceto Agricultural Chemicals Corporation (“AACC”), a wholly-owned subsidiary of the Company. In the lawsuit, UPL alleges, among other things, that AACC breached a 1995 agreement regarding European sales of a potato sprout suppression product, by selling the product in Europe. UPL claims damages of approximately £4,500 (approximately US $7,200) plus an unspecified amount of additional damages. AACC strongly denies the allegations and believes that UPL’s claims are without merit. However, in October 2014, in order to avoid the inherent risk of litigation, AACC and UPL reached an agreement pursuant to which (i) UPL will provide certain future business benefits and opportunities to AACC and the Company, and (ii) AACC would pay $350 to UPL, which occurred in December 2014.
	In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company’s financial condition or liquidity.
	The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale.  Based on continued monitoring of the contamination at the site and the approved plan of remediation, the Company received an estimate from an environmental consultant stating that the costs of remediation could be between $12,200 and $14,000.  Remediation commenced in fiscal 2010, and as of March 31, 2015 and June 30, 2014, a liability of $7,038 and $8,907, respectively, is included in the accompanying consolidated balance sheets for this matter. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale.  An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.
	In connection with the environmental remediation obligation for Arsynco, in July 2009, the Company entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of March 31, 2015 and June 30, 2014 is $3,167 and $4,008, respectively, which is included in the accompanying consolidated balance sheets.
	In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry’s Creek; any such claim with respect to Berry’s Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the “NJDEP Litigation”) and were considering impleading Arsynco into same. Arsynco entered into agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not known.
	A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (“FIFRA”).  FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,045 through fiscal 2015, of which $0 has been accrued as of March 31, 2015 and June 30, 2014.
	On December 31, 2010, the Company acquired certain assets of Rising Pharmaceuticals, Inc. (“Rising”),  a New Jersey based company that markets and distributes generic prescription and over the counter pharmaceutical products to leading wholesalers, chain drug stores, distributors, mass market merchandisers and others under its own label, throughout the United States. The purchase agreement provided for the payment of additional contingent consideration equal to one-half of the three year cumulative Rising earnings before interest, taxes, depreciation and amortization in excess of $32,100, up to a maximum of $6,000. In December 2014 and March 2015, the Company made payments of $1,500 to the former owners of Rising.  As of March 31, 2015 and June, 30, 2014, the Company had accrued $2,937 and $5,694, respectively, related to this contingent consideration.
	On April 30, 2014, Rising, a wholly owned subsidiary of Aceto, acquired 100% of the issued and outstanding membership interests of PACK. PACK, a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products, had headquarters in Buffalo Grove, Illinois, a suburb of Chicago, Illinois. The purchase agreement provides for a three-year earn-out of up to $15,000 in cash based on the achievement of certain performance-based targets.  As of March 31, 2015 and June 30, 2014, the Company accrued $4,133 and $3,797, respectively, related to this contingent consideration. Any necessary future adjustments to this amount will be recorded as an income statement charge at that time.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	(7) Fair Value Measurements
	GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs).  The hierarchy consists of three levels:
	Level 1 –   Quoted market prices in active markets for identical assets or liabilities;
	Level 2 –   Inputs other than Level 1 inputs that are either directly or indirectly observable; and
	Level 3 –   Unobservable inputs that are not corroborated by market data.
	On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets.  Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges.  Time deposits are short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions.  Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price.   Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At March 31, 2015, the Company had foreign currency contracts outstanding that had a notional amount of $54,495. Unrealized (losses) gains on hedging activities for the nine months ended March 31, 2015 and 2014 was ($2,517) and $75, respectively, and are included in interest and other income, net, in the condensed consolidated statements of income. The contracts have varying maturities of less than one year.
	In conjunction with the Credit Agreement, the Company entered into an interest rate swap on April 30, 2014 for an additional interest cost of 1.63% on a notional amount of $25,750, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is April 30, 2019. The remaining notional balance of this derivative as of March 31, 2015 is $28,000. Pursuant to the requirements of the Credit Agreement, dated December 31, 2010, the Company was required to deliver Hedging Agreements (as defined in the agreement) fixing the interest rate on not less than $20,000 of the term loan at that time. Accordingly, in March 2011, the Company entered into an interest rate swap for an additional interest cost of 1.91% on a notional amount of $20,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 31, 2015. The remaining balance of this derivative as of March 31, 2015 is $4,000. The unrealized loss to date associated with these two derivatives, which is recorded in accumulated other comprehensive income in the consolidated balance sheet at March 31, 2015, is $439. Aceto’s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates.
	As of March 31, 2015 and June 30, 2014, the Company had $2,937 and $5,694, respectively, of contingent consideration that was recorded at fair value in the Level 3 category, which related to the acquisition of Rising that was completed during fiscal 2011. In addition, as of March 31, 2015 and June 30, 2014, the Company had $4,133 and $3,797, respectively, of contingent consideration related to the PACK acquisition, which was completed in April 2014 and $303 and $413, respectively, of contingent consideration related to the acquisition of a company in France, which occurred in December 2013.  The contingent consideration was calculated using the present value of a probability weighted income approach.
	During the fourth quarter of each year, the Company evaluates goodwill and indefinite-lived intangibles for impairment at the reporting unit level using a cash flow model using Level 3 inputs. Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment. Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value.  Measurements based on undiscounted cash flows are considered to be Level 3 inputs.
	The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at March 31, 2015 and June 30, 2014:
			Fair Value Measurements at March 31, 2015 Using
					Significant		Significant
			Quoted Prices		Other		Unobservable Inputs
			in Active		Observable		(Level 3)
			Markets		Inputs (Level 2)				Total
			(Level 1)
	Cash equivalents:
	Time deposits			-	$	6,253		-	$	6,253
	Investments:
	Time deposits			-		1,834		-		1,834
	Foreign currency contracts-assets (1)			-		424		-		424
	Foreign currency contracts-liabilities (2)			-		2,635		-		2,635
	Derivative liability for interest rate swap (3)			-		439		-		439
	Contingent consideration (4)			-		-	$	7,373		7,373
	-1	Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
	(2)          Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
	-3	$28 included in “Accrued expenses” and $411 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
	-4	$2,937 included in “Accrued expenses” and $4,436 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
			Fair Value Measurements at June 30, 2014 Using
			Quoted Prices							Total
			in Active		Significant			Significant
			Markets		Other			Unobservable
			(Level 1)		Observable			Inputs
					Inputs (Level 2)			(Level 3)
	Cash equivalents:
	Time deposits			-	$	1,372		-	$	1,372
	Investments:
	Time deposits			-		746		-		746
	Foreign currency contracts-assets (5)			-		87		-		87
	Foreign currency contracts-liabilities (6)			-		128		-		128
	Derivative liability for interest rate swap (7)			-		437		-		437
	Contingent consideration (8)			-		-	$	9,904		9,904
	-5	Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
	(6)          Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
	-7	Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
	-8	$4,500 included in “Accrued expenses” and $5,404 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
	The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments.  The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Mar. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	(8)  Recent Accounting Pronouncements
	In February 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. ASU 2015-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. The Company believes the adoption of ASU 2015-02 will not have an impact on its consolidated financial statements.
	In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40).” This ASU provides guidance to determine when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. ASU 2014-15 will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. ASU 2014-15 will be effective for the Company beginning June 30, 2017. The Company does not believe that this pronouncement will have an impact on its consolidated financial statements.
	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under GAAP. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for annual and interim periods beginning on or after December 15, 2016, and early adoption is not permitted. Entities will have the option of using either a full retrospective approach or a modified approach to adopt the guidance. The Company is currently evaluating the impact of adopting this guidance.

Segment_Information

Segment Information	9 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Information	(9)  Segment Information
	The Company’s business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.
	Human Health - includes finished dosage form generic drugs and nutraceutical products.
	Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).
	Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals which make plastics, surface coatings, textiles, fuels and lubricants perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals. In addition, Aceto is a supplier of diazos and couplers to the paper, film and electronics industries.
	Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth. The Agricultural Protection Products segment also includes a sprout inhibitor for potatoes and an herbicide for sugar cane.
	The Company’s chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments’ performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP,  the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas:  (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.
	Nine Months Ended March 31, 2015 and 2014:
	Human		Pharmaceutical Ingredients		Performance		Unallocated Corporate		Consolidated Totals
	Health				Chemicals
	2015
	Net sales	$	160,808	$	111,104	$	128,452	$	-		$	400,364
	Gross profit		50,829		19,750		23,689		-			94,268
	Income (loss) before income taxes		21,096		5,393		9,925		(4,658	)		31,756
	2014
	Net sales	$	112,457	$	133,746	$	124,396	$	-		$	370,599
	Gross profit		34,244		30,443		20,994		-			85,681
	Income (loss) before income taxes		14,961		17,328		9,008		(5,089	)		36,208
	Three months Ended March 31, 2015 and 2014:
		Human
		Health		Pharmaceutical Ingredients		Performance		Unallocated Corporate			Consolidated Totals
						Chemicals
	2015
	Net sales	$	56,305	$	40,548	$	48,943	$	-		$	145,796
	Gross profit		19,957		6,674		9,967		-			36,598
	Income (loss) before income taxes		8,667		1,533		5,105		(1,679	)		13,626
	2014
	Net sales	$	33,946	$	47,843	$	43,041	$	-		$	124,830
	Gross profit		10,076		7,408		7,479		-			24,963
	Income (loss) before income taxes		3,234		2,798		3,555		(1,683	)		7,904

Net_Income_Per_Common_Share_Ta

Net Income Per Common Share (Tables)	9 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding
		Nine months ended				Three months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Weighted average shares outstanding		28,710		27,888		28,773		28,087
	Dilutive effect of stock options and restricted stock awards and units		506		582		494		519
	Diluted weighted average shares outstanding		29,216		28,470		29,267		28,606

Debt_Tables

Debt (Tables)	9 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of long-term debt
		March 31,		June 30,
		2015		2014
	Revolving bank loans	$	40,000	$	32,000
	Term bank loans		64,000		70,000
	Mortgage		3,207		3,355
	Other		-		146
			107,207		105,501
	Less current portion		9,697		8,343
		$	97,510	$	97,158
Schedule of outstanding unpaid principal amount of the term loan	Installment	Amount
	1 through 4	$	2,000
	5 through 8	$	2,500
	9 through 12	$	3,000
	13 through 16	$	4,000
	17 through 19	$	6,000

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Summary of valuation of the Company's financial assets and liabilities			Fair Value Measurements at March 31, 2015 Using
					Significant		Significant
			Quoted Prices		Other		Unobservable Inputs
			in Active		Observable		(Level 3)
			Markets		Inputs (Level 2)				Total
			(Level 1)
	Cash equivalents:
	Time deposits			-	$	6,253		-	$	6,253
	Investments:
	Time deposits			-		1,834		-		1,834
	Foreign currency contracts-assets (1)			-		424		-		424
	Foreign currency contracts-liabilities (2)			-		2,635		-		2,635
	Derivative liability for interest rate swap (3)			-		439		-		439
	Contingent consideration (4)			-		-	$	7,373		7,373
	-1	Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
	(2)          Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
	-3	$28 included in “Accrued expenses” and $411 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
	-4	$2,937 included in “Accrued expenses” and $4,436 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
			Fair Value Measurements at June 30, 2014 Using
			Quoted Prices							Total
			in Active		Significant			Significant
			Markets		Other			Unobservable
			(Level 1)		Observable			Inputs
					Inputs (Level 2)			(Level 3)
	Cash equivalents:
	Time deposits			-	$	1,372		-	$	1,372
	Investments:
	Time deposits			-		746		-		746
	Foreign currency contracts-assets (5)			-		87		-		87
	Foreign currency contracts-liabilities (6)			-		128		-		128
	Derivative liability for interest rate swap (7)			-		437		-		437
	Contingent consideration (8)			-		-	$	9,904		9,904
	-5	Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
	(6)          Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
	-7	Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
	-8	$4,500 included in “Accrued expenses” and $5,404 included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of segment performance measures	Nine Months Ended March 31, 2015 and 2014:
	Human		Pharmaceutical Ingredients		Performance		Unallocated Corporate		Consolidated Totals
	Health				Chemicals
	2015
	Net sales	$	160,808	$	111,104	$	128,452	$	-		$	400,364
	Gross profit		50,829		19,750		23,689		-			94,268
	Income (loss) before income taxes		21,096		5,393		9,925		(4,658	)		31,756
	2014
	Net sales	$	112,457	$	133,746	$	124,396	$	-		$	370,599
	Gross profit		34,244		30,443		20,994		-			85,681
	Income (loss) before income taxes		14,961		17,328		9,008		(5,089	)		36,208
	Three months Ended March 31, 2015 and 2014:
		Human
		Health		Pharmaceutical Ingredients		Performance		Unallocated Corporate			Consolidated Totals
						Chemicals
	2015
	Net sales	$	56,305	$	40,548	$	48,943	$	-		$	145,796
	Gross profit		19,957		6,674		9,967		-			36,598
	Income (loss) before income taxes		8,667		1,533		5,105		(1,679	)		13,626
	2014
	Net sales	$	33,946	$	47,843	$	43,041	$	-		$	124,830
	Gross profit		10,076		7,408		7,479		-			24,963
	Income (loss) before income taxes		3,234		2,798		3,555		(1,683	)		7,904

Stock_Based_Compensation_Narra

Stock Based Compensation (Narrative) (Detail) (USD $)	9 Months Ended		12 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 06, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$3,407	$2,416
Restricted Stock | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, vesting period	3 years		3 years
Common stock granted, shares	165		214
Restricted Stock | Non Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, vesting period	1 year		1 year
Common stock granted, shares	12		11
Performance-vested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	116		131
Upper limit of target grant, shares	203		196
Performance-vested restricted stock units, vesting percentage at the end of third year	100.00%		100.00%
Restricted Stock and Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3,368	2,225		1,123	606
Total unrecognized compensation cost	6,779			6,779
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$21	$175		$0	$30
Restricted stock units | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	67		32
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock that may be issued						5,250

Common_Stock_Narrative_Detail

Common Stock (Narrative) (Detail) (USD $)	0 Months Ended
	Feb. 05, 2015	Dec. 04, 2014	Sep. 04, 2014	7-May-15	8-May-14
Dividends Payable [Line Items]
Common Stock, Dividends, Per Share, Declared	$0.06	$0.06	$0.06
Dividends declared, date of declaration	5-Feb-15	4-Dec-14	4-Sep-14
Dividends declared, date of distribution	26-Mar-15	29-Dec-14	29-Sep-14
Dividends declared, date of record	12-Mar-15	15-Dec-14	15-Sep-14
Stock repurchase program
Dividends Payable [Line Items]
Number of shares authorized to be repurchased					5,000
Subsequent Event
Dividends Payable [Line Items]
Common Stock, Dividends, Per Share, Declared				$0.06
Dividends declared, date of declaration				7-May-15
Dividends declared, date of distribution				25-Jun-15
Dividends declared, date of record				11-Jun-15

Net_Income_Per_Common_Share_Re

Net Income Per Common Share (Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Weighted average shares outstanding	28,773	28,087	28,710	27,888
Dilutive effect of stock options and restricted stock awards and units	494	519	506	582
Diluted weighted average shares outstanding	29,267	28,606	29,216	28,470

Debt_Summary_of_Longterm_Debt_

Debt (Summary of Long-term Debt) (Detail) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Long-term debt including current portion	$107,207	$105,501
Less current portion	9,697	8,343
Long-term debt	97,510	97,158
Revolving bank loans
Debt Instrument [Line Items]
Long-term debt including current portion	40,000	32,000
Term bank loans
Debt Instrument [Line Items]
Long-term debt including current portion	64,000	70,000
Less current portion	9,500
Mortgage
Debt Instrument [Line Items]
Long-term debt including current portion	3,207	3,355
Other
Debt Instrument [Line Items]
Long-term debt including current portion		$146

Debt_Summary_of_Quarterly_Inst

Debt (Summary of Quarterly Installments of Term Loans) (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Installments 1 through 4
Debt Instrument [Line Items]
Periodic installment amount	$2,000
Installments 5 through 8
Debt Instrument [Line Items]
Periodic installment amount	2,500
Installments 9 through 12
Debt Instrument [Line Items]
Periodic installment amount	3,000
Installments 13 through 16
Debt Instrument [Line Items]
Periodic installment amount	4,000
Installments 17 through 19
Debt Instrument [Line Items]
Periodic installment amount	$6,000

Debt_Narrative_Detail

Debt (Narrative) (Detail) (USD $)	1 Months Ended	9 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Mar. 31, 2015	Jun. 30, 2011	Jun. 30, 2014
Debt Instrument [Line Items]
Short term loans payable		$9,697		$8,343
Revolving bank loans
Debt Instrument [Line Items]
Loans, maximum amount	60,000
Revolving loans, expiration date	30-Apr-19
Bank loans outstanding		40,000
Lines of credit, variable rate basis		LIBOR
Revolving bank loans | Minimum
Debt Instrument [Line Items]
Adjusted LIBOR Loans at interest rates		2.22%
Revolving bank loans | Maximum
Debt Instrument [Line Items]
Adjusted LIBOR Loans at interest rates		2.32%
Term bank loans
Debt Instrument [Line Items]
Loans, maximum amount		70,000
Bank loans outstanding		64,000
Adjusted LIBOR Loans at interest rates		2.28%
Term loans, number of installments		19
Short term loans payable		9,500
Mortgage payable
Debt Instrument [Line Items]
Adjusted LIBOR Loans at interest rates		4.92%
Mortgage payable			3,947
Mortgage payable, amortization period			20 years
Open letter of credit
Debt Instrument [Line Items]
Letters of credit		$21		$105

Commitments_Contingencies_and_1

Commitments, Contingencies and Other Matters (Narrative) (Detail)

9 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Mar. 31, 2015

Mar. 31, 2015

Dec. 31, 2014

Jun. 30, 2014

Dec. 31, 2010

Apr. 30, 2014

Mar. 31, 2015

Jun. 30, 2014

Dec. 31, 2014

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Jun. 30, 2014

Jul. 31, 2009

Mar. 31, 2015

Jun. 30, 2014

Mar. 31, 2015

Jun. 30, 2014

USD ($)

Rising Pharmaceuticals Inc.

Rising Pharmaceuticals Inc.

Rising Pharmaceuticals Inc.

Rising Pharmaceuticals Inc.

Pack Pharmaceuticals Llc

Pack Pharmaceuticals Llc

Pack Pharmaceuticals Llc

United Phosphorous Limited

United Phosphorous Limited

United Phosphorous Limited

Pulvair Site Group

Arsynco, Inc

Arsynco, Inc

BASF Corporation

BASF Corporation

BASF Corporation

Subsidiary

Subsidiary

Entity

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

GBP (£)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Commitments and Contingencies Disclosure [Line Items]

Loss contingency, damages sought

$7,200

£ 4,500

$1,700

Payment for litigation settlement

350

Site contingency loss exposure not accrued, low estimate

12,200

Site contingency loss exposure not accrued, high estimate

14,000

Accrual for environmental loss contingencies

7,038

8,907

Partial reimbursement of environmental remediation costs previously expensed

550

Environmental remediation costs expensed in prior years

1,200

Future remediation costs receivable

3,167

4,008

Number of potentially responsible parties

150

Amount expected to be paid for product registrations and various task force groups

2,045

Amount accrued for product registrations and various task force groups

0

0

Earnings before interest taxes, depreciation and amortization

32,100

Contingent consideration, maximum

6,000

Payment to former owners

3,000

1,500

1,500

Percentage of issued and outstanding membership interests acquired

100.00%

Purchase price, earn-out period

3 years

Purchase price, maximum earn-out amount

15,000

Accrued contingent consideration

$2,937

$5,694

$4,133

$3,797

Fair_Value_Measurements_Summar

Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Detail) (USD $)	Mar. 31, 2015		Jun. 30, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	$424	[1]	$87	[2]
Foreign currency contracts-liabilities	2,635	[3]	128	[4]
Derivative liability for interest rate swap	439	[5]	437	[6]
Contingent consideration	7,373	[7]	9,904	[8]
Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	6,253		1,372
Investments	1,834		746
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets		[1]		[2]
Foreign currency contracts-liabilities		[3]		[4]
Derivative liability for interest rate swap		[5]		[6]
Contingent consideration		[7]		[8]
Quoted Prices in Active Markets (Level 1) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Investments
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	424	[1]	87	[2]
Foreign currency contracts-liabilities	2,635	[3]	128	[4]
Derivative liability for interest rate swap	439	[5]	437	[6]
Contingent consideration		[7]		[8]
Significant Other Observable Inputs (Level 2) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	6,253		1,372
Investments	1,834		746
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets		[1]		[2]
Foreign currency contracts-liabilities		[3]		[4]
Derivative liability for interest rate swap		[5]		[6]
Contingent consideration	7,373	[7]	9,904	[8]
Significant Unobservable Inputs (Level 3) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Investments
[1]	Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
[2]	Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
[3]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
[4]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
[5]	$28 included in "Accrued expenses" and $411 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
[6]	Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
[7]	$2,937 included in "Accrued expenses" and $4,436 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
[8]	$4,500 included in "Accrued expenses" and $5,404 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.

Fair_Value_Measurements_Summar1

Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Parentheticals) (Detail) (USD $)	Mar. 31, 2015		Jun. 30, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability for interest rate swap	$439	[1]	$437	[2]
Contingent consideration	7,373	[3]	9,904	[4]
Accrued expenses
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability for interest rate swap	28
Contingent consideration	2,937		4,500
Long-term liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability for interest rate swap	411
Contingent consideration	$4,436		$5,404
[1]	$28 included in "Accrued expenses" and $411 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
[2]	Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.
[3]	$2,937 included in "Accrued expenses" and $4,436 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2015.
[4]	$4,500 included in "Accrued expenses" and $5,404 included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2014.

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Detail) (USD $)	9 Months Ended		1 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Apr. 30, 2014	Mar. 31, 2011	Jun. 30, 2014
Rising Pharmaceuticals Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration at fair value	$2,937				$5,694
PACK Pharmaceuticals, LLC
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration at fair value	4,133				3,797
France Company
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration at fair value	303				413
Foreign exchange contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	54,495
Unrealized gains (losses) on hedging activities	-2,517	75
Interest rate swap | Cash flow hedging
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized loss recorded in accumulated other comprehensive income	439
Interest rate swap | Cash flow hedging | April 30, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	28,000		25,750
Derivative, interest rate			1.63%
Derivative, expiration date			30-Apr-19
Interest rate swap | Cash flow hedging | December 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	$4,000			$20,000
Derivative, interest rate				1.91%
Derivative, expiration date				31-Dec-15

Segment_Information_Summary_of

Segment Information (Summary of Segment Perfomance Measures by Segment) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Net sales	$145,796	$124,830	$400,364	$370,599
Gross profit	36,598	24,963	94,268	85,681
Income (loss) before income taxes	13,626	7,904	31,756	36,208
Operating Segments | Human Health
Segment Reporting Information [Line Items]
Net sales	56,305	33,946	160,808	112,457
Gross profit	19,957	10,076	50,829	34,244
Income (loss) before income taxes	8,667	3,234	21,096	14,961
Operating Segments | Pharmaceutical Ingredients
Segment Reporting Information [Line Items]
Net sales	40,548	47,843	111,104	133,746
Gross profit	6,674	7,408	19,750	30,443
Income (loss) before income taxes	1,533	2,798	5,393	17,328
Operating Segments | Performance Chemicals
Segment Reporting Information [Line Items]
Net sales	48,943	43,041	128,452	124,396
Gross profit	9,967	7,479	23,689	20,994
Income (loss) before income taxes	5,105	3,555	9,925	9,008
Unallocated Corporate
Segment Reporting Information [Line Items]
Net sales
Gross profit
Income (loss) before income taxes	($1,679)	($1,683)	($4,658)	($5,089)

Segment_Information_Narrative_

Segment Information (Narrative) (Detail)	9 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of operating segments	3